In vitro activity of ceftazidime-avibactam against carbapenem-resistant and hypervirulent klebsiella pneumoniae isolates

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 8, 2018, Pages

  Yu, Fangyou ^a,b   Lv, Jingnan ^b   Niu, Siqiang ^c   Du, Hong ^d   Tang, Yi Wei ^e,i   Bonomo, Robert A ^f,g   Kreiswirth, Barry N ^h   Chen, Liang ^h  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^d THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^h PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Carbapenem resistance; Ceftazidime avibactam; Hypervirulent Klebsiella pneumoniae; Susceptibility

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BACTERIAL ENZYME; BETA LACTAMASE CTX M; BETA LACTAMASE SHV; BETA LACTAMASE TEM 1; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; GENTAMICIN; IMIPENEM; KLEBSIELLA PNEUMONIAE CARBAPENEMASE 2; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CARBAPENEMASE-2, KLEBSIELLA PNEUMONIAE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CARBAPENEM RESISTANT AND HYPERVIRULENT KLEBSIELLA PNEUMONIAE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; IUTA GENE; KLEBSIELLA PNEUMONIAE; MIC50; MIC90; MULTILOCUS SEQUENCE TYPING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RMPA GENE; SANGER SEQUENCING; DRUG COMBINATION; DRUG EFFECT; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CEFTAZIDIME; DRUG COMBINATIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 85052024457     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01031-18     Document Type: Article

References (17)

1. Gu D, Dong N, Zheng Z, Lin D, Huang M, Wang L, Chan EW, Shu L, Yu J, Zhang R, Chen S. 2018. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. Lancet Infect Dis 18:37–46. https://doi.org/10.1016/S1473-3099(17)30489-9.
2. Catalán-Nájera JC, Garza-Ramos U, Barrios-Camacho H. 2017. Hyperviru-lence and hypermucoviscosity: two different but complementary Klebsiella spp. phenotypes? Virulence 8:1111–1123. https://doi.org/10.1080/21505594.2017.1317412.
3. van Duin D, Bonomo RA. 2016. Ceftazidime/avibactam and ceftolozane/ tazobactam: second-generation beta-lactam/beta-lactamase inhibitor combinations. Clin Infect Dis 63:234–241. https://doi.org/10.1093/cid/ciw243.
4. KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/AAC.02097-16.
5. Barnes MD, Winkler ML, Taracila MA, Page MG, Desarbre E, Kreiswirth BN, Shields RK, Nguyen MH, Clancy C, Spellberg B, Papp-Wallace KM, Bonomo RA. 2017. Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from beta-lactamase protein engineering. mBio 8:e00528-17. https://doi.org/10 .1128/mBio.00528-17.
6. Shon AS, Bajwa RP, Russo TA. 2013. Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed. Virulence 4:107–118. https://doi.org/10.4161/viru.22718.
7. Lee CR, Lee JH, Park KS, Jeon JH, Kim YB, Cha CJ, Jeong BC, Lee SH. 2017. Antimicrobial resistance of hypervirulent Klebsiella pneumoniae: epidemiology, hypervirulence-associated determinants, and resistance mechanisms. Front Cell Infect Microbiol 7:483. https://doi.org/10.3389/fcimb.2017.00483.
8. Russo TA, Olson R, MacDonald U, Beanan J, Davidson BA. 2015. Aero-bactin, but not yersiniabactin, salmochelin, or enterobactin, enables the growth/survival of hypervirulent (hypermucoviscous) Klebsiella pneumoniae ex vivo and in vivo. Infect Immun 83:3325–3333. https://doi.org/10.1128/IAI.00430-15.
9. Fang CT, Chuang YP, Shun CT, Chang SC, Wang JT. 2004. A novel virulence gene in Klebsiella pneumoniae strains causing primary liver abscess and septic metastatic complications. J Exp Med 199:697–705. https://doi.org/10.1084/jem.20030857.
10. CLSI. 2018. Performance standards for antimicrobial susceptibility testing; M100-S28. CLSI, Wayne, PA.
11. Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. 2005. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol 43:4178 – 4182. https://doi.org/10.1128/JCM.43.8.4178-4182.2005.
12. Clancy CJ, Chen L, Hong JH, Cheng S, Hao B, Shields RK, Farrell AN, Doi Y, Zhao Y, Perlin DS, Kreiswirth BN, Nguyen MH. 2013. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother 57:5258–5265. https://doi.org/10.1128/AAC.01069-13.
13. Brisse S, Passet V, Haugaard AB, Babosan A, Kassis-Chikhani N, Struve C, Decre D. 2013. wzi gene sequencing, a rapid method for determination of capsular type for Klebsiella strains. J Clin Microbiol 51:4073– 4078. https://doi.org/10.1128/JCM.01924-13.
14. Dong N, Zhang R, Liu L, Li R, Lin D, Chan EW, Chen S. 8 February 2018. Genome analysis of clinical multilocus sequence type 11 Klebsiella pneumoniae from China. Microb Genom https://doi.org/10.1099/mgen.0.000149.
15. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16:161–168. https://doi.org/10.1016/S1473-3099(15)00424-7.
16. van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler VG, Jr, Paterson DL, Bonomo RA, Evans S, Antibacterial Resistance Leadership Group. 2018. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 66:163–171. https://doi.org/10.1093/cid/cix783.
17. Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Doi Y, Kreiswirth BN, Clancy CJ. 2017. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 61:e00883-17. https://doi.org/10.1128/AAC.00883-17.